The noise around rapid COVID testing (RAT) in the media is increasing in volume. Premiers and medical experts are starting to recognize the need and have started using these tests.

Anteotech's Eugeni reader  is fast accurate and can store data. The data storage will be important for mass testing at borders, stadiums, airports, FIFO workplaces, large employers.

Sales news for Anteotech has been slow but they have signed up distributors in UK, Aus, SE Asia with more expected to be signed up soon. These areas have an estimated population of approximately 500 million people. The distributors are working on final approvals for sales in these areas.

The company has been quiet of late regarding sales even, though they were quite vocal about 'upcoming sales' earlier in the year. I am hopeful that this delay is due to the final approval process for each country/area. 

Until  solid sales are confirmed the share price will continue to languish and the fear that they have missed the boat will increase. I think the market is huge and growing and will be around for a lot longer than we would like. I anticipate news on sales to start around late September.

AnteoTech has lifted its Trading Halt with this annoucement &  Presentation 

1. AnteoTech secures new funding to support sales launch and accelerate test pipeline (attached)

Highlights

•  AnteoTech receives firm commitments to raise $12m through the issue of ~46.2m new fully paid ordinary shares at $0.26 per share
•  Funds to be used to scale up the roll-out of the EuGeni reader and COVID-19 ART, and accelerate the development of other assay tests
•  Placement was strongly supported by new institutional and sophisticated investors
•  Share Purchase Plan to be launched to raise additional $4m from eligible, existing shareholders at $0.26 per share,

2. Investor Presentation

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02367876-2A1294780?access_token=83ff96335c2d45a094df02a206a39ff4

The Cap Raise & SPP price is 26cps. the share closing price was 41.5cps and now (2:45pm) is 42cps.

DISC: I hold

1.Energy Collaborator Program Creates Commercialisation Pathway for AnteoX (attached)

Highlights

•  Initial assessment of AnteoX completed by Collaborator 8 confirms AnteoTech’s results of electrochemical performance enhancement.
• Collaborator 8 and AnteoTech move into a new phase of collaboration focused on customer trials and supply agreement.
•  AnteoX assessment undertaken by Collaborators 5 and 6 reveals untapped potential of using AnteoX as a binder additive.
•  Increased focus on commercialisation of AnteoX combined with commonly available binder products.

AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to report that evaluation work conducted by AnteoTech’s Collaborators, focusing on the application of AnteoX, has proven very successful. The collaborative work and results have strengthened partnerships and created a pathway to commercialisation of AnteoX.

2.Request for Trading Halt

1.  the trading halt is requested pending an announcement by the Company concerning a capital raising;
2.  the Company requests that the trading halt remain in place until the commencement of trading on Wednesday 28 April 2021 unless before that time the Company makes an announcement in relation to the capital raising; and
3.  the Company is not aware of any reason why the trading halt should not be granted

12/4/21  AnteoTech Rapid Test Platform and COVID-19 Test Receive CE Mark Registration

EUGENI

Highlights

•  Reader and test platform trademarked – EuGeni
•  EuGeni product launch event and webcast end April 2021
•  CE Mark registration achieved for EuGeni Rapid Test Platform and COVID-19 Antigen Rapid Test (ART) based on proprietary AnteoBind Activated Europium technology
•  EuGeni Rapid Test Platform is expected to create a new revenue stream and a leverage opportunity to develop further rapid tests, maximising reader capability

Disc: I hold.....now they will be able to sign contracts and do sales in Europe 

AnteoTech Joins $130M Future Battery Industries CRC

Highlights

•  AnteoTech signs participation agreement for the Future Battery Industries CRC Super Anode Project
•  AnteoTech to be the sole supplier of silicon composite material to the Super Anode Project
•  AnteoTech to retain all of its Intellectual Property (IP) rights and gain share in Project IP

The Super Anode Project is a four-year project with the aim of developing the materials, processes and cell-level technology to kick-start Australia’s battery industry and complement the FBICRCs cathode precursor refinement and material development project.

The Super Anode Project will deliver on two equally funded project areas.

1.  The development of flake graphite production in Australia by adding value to Australia’s natural graphite reserves by creating “step change” improvements in processing and ensuring Australian natural graphite meets the high standards of global battery manufacturers.
2.  Secondly, the development of high-capacity silicon-containing anodes that meet future national and global capacity requirements by designing silicon composite materials and integrating them with Australian natural graphite.

Disc: Small holding

European production and sales of rapid, accurate COVID antigen test to start any day.

Ellume production ramping up to deliver home COVID tests to the US Department of Defence. Anteotech chemistry is a crucial part of this test.

AnteoTech Customer Ellume Secure US Contract

Brisbane based nanotechnology company AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) notes our customer Ellume has made an announcement of an agreement with the U.S. Deppartment of Defense (DOD) for its Emergency Use Authorization (EUA) COVID 19 at home test.